Patients with AML Receiving Too Much Chemotherapy

TON - Daily

Patients with acute myeloid leukemia (AML) receive unnecessarily high-dose levels of chemotherapy, according to Dr Bob Löwenberg, professor of Hematology at the Erasmus University Medical Center in Rotterdam, The Netherlands at the 16th Congress of the European Hematology Association.

 

Löwenberg and his colleagues found that the level of cytarabine, a component of the standard regimen for this disease, received can be up to 10 times more than needed (range, 2000 to 3000 mg/m2 twice daily). Based on their large prospective randomized multicenter trial, the team identified the plateau dosage of 1000 mg/m2 for cytarabine, which producesequivalent results in response and relapse rates.

 

This lower dosage also lessened toxicities, resulting in shorter hospital stays and a reduced requirement for platelet transfusions. The team concluded, “These insights are likely to have an impact upon the standard of care of acute myeloid leukemia.”

 

Read the EHA announcement:

http://www.ehaweb.org/news/Patients-with-Acute-Myeloid-Leukemia-receive-unnecessary-high-doses-Chemotherapy-recent-study-reveals

Related Items


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: